Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources

• Published in: Advances in therapy 2023-03, Vol.40 (3), p.1129-1140
• Main Authors: Youn, Bora, Proud, Crystal M., Wang, Nasha, Hou, Qiang, Viscidi, Emma, Eaton, Susan, Paradis, Angela D., Neville, Bridget A., Johnson, Nicole B.
• Format: Article
• Language: English
• Subjects: Cardiology; Endocrinology; Humans; Information Sources; Insurance Claim Review; Internal Medicine; Medicine; Medicine & Public Health; Muscular Atrophy, Spinal - drug therapy; Oligonucleotides - therapeutic use; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology; United States
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-022-02414-9

Introduction Spinal muscular atrophy (SMA) is a rare neuromuscular disease characterized by progressive muscular atrophy and weakness. Nusinersen was the first treatment approved for SMA. Per the US label, the nusinersen administration schedule consists of three loading doses at 14-day intervals, a fourth loading dose 30 days later, and maintenance doses every 4 months thereafter. Using two large US databases, we evaluated real-world adherence to nusinersen with its unique dosing schedule among generalizable populations of patients with SMA. Methods Patients with SMA treated with nusinersen, likely to have complete information on date of treatment initiation, were identified in the Optum ® de-identified electronic health records (EHR) database (7/2017–9/2019), and in the Merative™ MarketScan ® Research Databases from commercial (1/2017–6/2020) and Medicaid claims (1/2017–12/2019). Baseline demographics, number of nusinersen administrations on time, and distribution of inter-dose intervals were summarized. Results Totals of 67 and 291 patients were identified in the EHR and claims databases, respectively. Most nusinersen doses were received on time (93.9% EHR, 80.5% claims). Adherence was higher during the maintenance phase (90.6%) than the loading phase (71.1%) in the claims analysis, in contrast with the EHR analysis (95.5% and 92.6%, respectively), suggesting that not all loading doses of nusinersen may be accurately captured in claims. Inter-dose intervals captured in both databases aligned with the expected dosing schedule. Conclusion Most nusinersen doses were received on time, consistent with the recommended schedule. Our findings also highlight the importance of careful methodological approaches when using real-world administrative databases for evaluation of nusinersen treatment patterns. Plain Language Summary Adherence to medicines in the real world is important for patients with chronic disease to see long-term benefits of treatment. This study shows the importance and challenges of measuring adherence using real-world administrative data sources. This is especially important for drugs given through lumbar puncture with unique dosing schedules, such as nusinersen for the treatment of spinal muscular atrophy. In this study, most patients with spinal muscular atrophy received their nusinersen doses on time.